Trial · NCT01949324
A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel
NCT01949324, Phase 2, Completed, Neurotech Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel. Trials, record NCT01949324. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01949324
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel
- NCT number
- NCT01949324
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 67 participants, actual
- Lead sponsor
- Neurotech Pharmaceuticals
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- Ciliary neurotrophic factor (CNTF), Sham procedure, NT-501 Implant, NT-501 Implant procedure
- First posted
- 2013-09-24
- Last updated
- 2018-09-12
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ellipsoid zone (area of IS/OS loss) as measured by en face imagining by SDOCT in study eye(s) | 24 months | Change in the ellipsoid zone (area of IS/OS loss) from baseline to month 24 as measured by en face imaging by SDOCT in study eye(s) |
| Secondary | Ellipsoid zone | 12 months | Change in the ellipsoid zone from baseline to Month 12. |
| Secondary | Retinal sensitivity (dB) as measured by microperimetry | 12 and 24 months | Change in retinal sensitivity (dB) as measured by microperimetry from baseline to Months 12 and 24. |
| Secondary | Increase in ellipsoid zone | 12 and 24 months | Proportion of study eyes with a 35% or more increase from baseline in the ellipsoid zone at Months 12 and 24. |
| Secondary | Visual Acuity | 12 and 24 months | Change in best corrected visual acuity (BCVA) from baseline to Months 12 and 24. |
| Secondary | Visual Acuity | 12 and 24 Months | Proportion of study eyes with 15 or more letter loss from baseline in BCVA at Months 12 and 24. |
| Secondary | Visual Acuity | 12 and 24 Months | Proportion of study eyes with 10 or more letter loss from baseline in BCVA at Months 12 and 24. |
| Secondary | Reading Speed | 12 and 24 Months | Change in reading speed as measured by the IReST from baseline to Months 12 and 24. |
| Other | Cone density as measured by AOSLO | 12 and 24 Months | Change in cone density as measured by AOSLO from baseline to Months 12 and 24, in selected participants. |
| Other | National Eye Institute Visual Functioning Questionnaire | 12 and 24 months | Change in NEI VFQ (overall and subscale) from baseline to Months 12 and 24. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33229343 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01949324
GET https://conductscience.org/api/trials/v1/NCT01949324/registered